Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group
Mariana Brandão(Institut Jules Bordet), Torsten Blum(MSB Medical School Berlin), Enrico Ruffini(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Corinne Faivre‐Finn(University of Manchester), Koen J. Hartemink(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Caroline Caramella(Institut Gustave Roussy), Antonin Lévy(Inserm), Elena Prisciandaro(Universitair Ziekenhuis Leuven), Constance de Margerie‐Mellon(Université Paris Cité), Egbert F. Smit(Dutch Cancer Society), Andrea Riccardo Filippi(University of Turin), Mario Occhipinti(Fondazione IRCCS Istituto Nazionale dei Tumori), Matthias Gückenberger(University Hospital of Zurich), Jules L. Derks(Maastricht University Medical Centre), Francesco Cortiula(Ospedale Santa Maria della Misericordia di Udine), Ilias Houda(Amsterdam University Medical Centers), David Sánchez-Lorente(Hospital Clínic de Barcelona), John Edwards(Sheffield Teaching Hospitals NHS Foundation Trust), Élie Fadel(Université Paris-Sud), Paolo Bironzo(University of Turin), Safae Terrisse(Assistance Publique – Hôpitaux de Paris), Daniel Portik(European Organisation for Research and Treatment of Cancer), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Sanjay Popat(Royal Marsden NHS Foundation Trust), T. Pierret(Hôpital Louis Pradel), Emanuela Olmetto(Azienda Ospedaliero-Universitaria Careggi), René Horsleben Petersen(Johnson & Johnson (United States)), A. Bandura(Gdańsk Medical University), José Carlos Benítez(Hospital Regional Universitario de Málaga), Jordi Remón(Vall d'Hebron Hospital Universitari), Eleni Xenophontos(University of Cyprus), Alessio Vincenzo Mariolo(Institute Mutualiste Montsouris), Niccolò Giaj‐Levra(Ospedale Sacro Cuore Don Calabria), Idris Bahce(Amsterdam Neuroscience), Ronan Abgral(Centre Hospitalier Régional Universitaire de Brest), Amir H. Sadeghi(Shahid Beheshti University of Medical Sciences), Élisa Gobbini(Institut Curie), Olaf Mercier(Université Paris-Sud), Noemı́ Reguart(Hospital Clínic de Barcelona), Isabelle Opitz(University Hospital of Zurich), Juan Trujillo(University of Alicante), Paul Hofman(Inserm), Nicolas Girard(Institut Curie), Konstantinos Stathopoulos(Institut Jules Bordet), Karim Amrane(Centre Hospitalier des Pays de Morlaix), Riccardo De Angelis(Université Libre de Bruxelles), Lizza Hendriks(Maastricht University), Dirk De Ruysscher(Maastricht University Medical Centre), Chris Dickhoff(Amsterdam Neuroscience)
Cited by 10
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k